Latest OncoZenge News & Updates

See the latest news and media coverage for OncoZenge. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
OncoZenge

Developer of lozenges for oral mucositis pain relief

oncozenge.se
Headquarters
Stockholm, Sweden
Company type
Public company
Number of employees
4–10

Last updated

Latest news about OncoZenge

In short: OncoZenge received European regulatory approval to initiate a pivotal Phase III trial for BupiZenge and secured multiple rounds of funding.

Company announcements

OncoZenge

OncoZenges's annual general meeting approved the results and elected the board

Decision on no dividend, re-election of the chairman of the board, election of two new members, and introduction of a subscription option program for the board and management.

Unlock all announcements with a

Media coverage

FinanzNachrichten

OncoZenge AB: OncoZenge Reports Positive Stability Results for BupiZenge as Key Enabler for the Upcoming Phase III Trial

OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the three-month stability study results for its BupiZenge lozenge...

Unlock all articles with a

Never miss news about OncoZenge

Track OncoZenge and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.